Castle Biosciences has a quick ratio of 9.19. It generally indicates good short-term financial strength.
The historical rank and industry rank for Castle Biosciences's Quick Ratio or its related term are showing as below:
CSTL'
s Quick Ratio Range Over the Past 10 Years
Min: 1.22 Med: 7.92 Max: 24.14
Current: 9.19
During the past 8 years, Castle Biosciences's highest Quick Ratio was 24.14. The lowest was 1.22. And the median was 7.92.
CSTL's Quick Ratio is ranked better than 92.69% of 219
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96
vs CSTL: 9.19
Castle Biosciences Quick Ratio Historical Data
The historical data trend for Castle Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Castle Biosciences's Quick Ratio
For the Diagnostics & Research subindustry, Castle Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Castle Biosciences's Quick Ratio Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Castle Biosciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Castle Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Castle Biosciences (NAS:CSTL) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Castle Biosciences Quick Ratio Related Terms
Thank you for viewing the detailed overview of Castle Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSTL has been successfully added to your 